Trial Profile
A phase II study of ONTAK [denileukin diftitox] alternate dosing of non-mycosis fungoides peripheral cutaneous T-cell lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2005
Price :
$35
*
At a glance
- Drugs Denileukin diftitox (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- 23 Dec 2005 New trial record.